Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355522 | 0.87 | THRB (0.35) | THRBLMNA | |
| SCHEMBL9714481 | 0.80 | THRB (0.38) | THRBLMNA | |
| SCHEMBL6721190 | 0.78 | THRB (0.36) | THRBLMNA | |
| SCHEMBL11488780 | 0.75 | THRB (0.44) | THRBLMNA | |
| SCHEMBL9714704 | 0.75 | THRB (0.44) | THRBLMNA | |
| SCHEMBL11602009 | 0.74 | ADRB2 (0.35) | — | |
| SCHEMBL1568155 | 0.73 | THRB (0.57) | THRBLMNA | |
| SCHEMBL6180838 | 0.73 | — | — | |
| SCHEMBL5182048 | 0.73 | LMNA (0.47) | THRBLMNA | |
| SCHEMBL7863883 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103415518-A | Imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment hyperproliferative disorders | BAYER IP GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| EP-2651948-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2185524-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| CN-101679277-A | Novel peptide inhibitors of hepatitis c virus replication | INTERMUNE INC | 2010-03-24 | — | — | CN | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1675858-A2 | 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| CN-1633419-A | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2005-06-29 | — | — | CN | disclosed |
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005028480-A2 | 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1392662-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096888-A1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | WO | disclosed |
| WO-1994027985-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-HALOMETHYL-BENZOTHIOPHENES, BENZOFURANS AND -INDOLES AND INTERMEDIATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1993019067-A1 | IMIDAZOPYRIDINE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | CRHR1, HTR5A, HTR1D | THRB 342/4885LMNA 1253/4885 |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | THRB 4115/4885LMNA 3054/4885 |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | TK1, CDKL1, CDK1 | THRB 1961/4885LMNA 2287/4885 |
| US-20040102630-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | THRB 2763/4885LMNA 2834/4885 |
| US-20040224966-A1 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | THRB 2747/4885LMNA 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.